The Treatment of COVID-19 Purgatory Syndrome With Tocilizumab and Steroids.
Cureus
; 14(2): e22614, 2022 Feb.
Article
in English
| MEDLINE | ID: covidwho-1776620
ABSTRACT
Hyperinflammation is a key component of severe coronavirus disease 2019 (COVID-19) and is associated with poor outcomes. It is imperative to distinguish severe COVID-19 from hyperinflammatory syndromes such as multisystem inflammatory syndrome (MIS) and hemophagocytic lymphohistiocytosis. There is a subset of post-COVID-19 patients who present with some symptoms characteristic of MIS in adults (MIS-A) yet do not meet all the criteria for a diagnosis. We describe the unique case of a patient with this kind of presentation who clinically improved following tocilizumab and corticosteroid usage.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Case report
/
Prognostic study
Topics:
Long Covid
Language:
English
Journal:
Cureus
Year:
2022
Document Type:
Article
Affiliation country:
Cureus.22614
Similar
MEDLINE
...
LILACS
LIS